Company will use its technology to characterize cancer mutations.!--h2>
Transgenomic signed a contract with OSI Pharmaceuticals to complete an analysis of specific cancer pathway genes. According to the company, it has developed a high-throughput, high-sensitivity methodology for characterizing genetic variants implicated in malignant neoplasia. Transgenomic can detect pathogenic genetic mutations through use of high-throughput genome scanning with endonucleases, forward and reverse Sanger sequencing, and variant annotation.
"The contract with OSI Pharmaceuticals enables Transgenomic to utilize its expertise in genetic variant detection to assist OSI Pharmaceuticals in its development efforts. This contract follows genetic analysis work done with other pharmaceutical companies. It is one of the ways Transgenomic can contribute to the development of therapeutics that benefits patients," states Transgenomic's president and CEO, Craig Tuttle.